An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
about
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewPsoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique backgroundA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisNucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance.The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea.Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals.Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation.Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response.Overexpression of Glucocorticoid-induced Leucine Zipper (GILZ) increases susceptibility to Imiquimod-induced psoriasis and involves cutaneous activation of TGF-β1.Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.The Role of IFN-β during the Course of Sepsis Progression and Its Therapeutic Potential.Amentoflavone protects against psoriasis-like skin lesion through suppression of NF-κB-mediated inflammation and keratinocyte proliferation.Cutaneous side effects of TNF-alpha inhibitors.A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers.Nebenwirkungen von TNF-alpha-Inhibitoren am Hautorgan.Therapeutic approaches for the delivery of TNF-α siRNA.Overexpression and potential roles of NRIP1 in psoriasis.Is there any increased risk of hypertension, diabetes and cardiac diseases in psoriatic patients with TNF-α G238A and G308A polymorphism?Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes.Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.Topical imiquimod yields systemic effects due to unintended oral uptake.NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL- 17 and TNF.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.Effects of Wannachawee Recipe with Antipsoriatic Activity on Suppressing Inflammatory Cytokine Production in HaCaT Human Keratinocytes.Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders.Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.The Immunogenetics of Psoriasis and Implications for Drug Repositioning.TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin.Methylation and Esterification of Magnolol for Ameliorating Cutaneous Targeting and Therapeutic Index by Topical Application.A New Venue of TNF Targeting.Foxp3 T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8 T cell responseTNIP1 in Autoimmune Diseases: Regulation of Toll-like Receptor Signaling
P2860
Q26738918-438794E6-B54C-4456-8CEC-04D541A2701BQ26765175-A928FF34-88E2-4224-B40F-19F738D1E6C9Q26771682-E582CF19-C7D4-41DF-B230-70E6DE35C608Q28085200-8BEEAEAA-2CD9-473B-BBE8-AD8D5EA1D8F8Q35922976-8BBD86D6-5743-4253-9BC4-662CEFCCDEBFQ36096242-FDCFE4BC-B472-4EDB-ACA5-34E5C1AB12BDQ36202783-BFEEABDA-3D57-4647-AAA7-DA840DE2A8D7Q36536816-9F691797-A791-4692-9E9E-B20DB7126E72Q36667189-93B21D44-4486-47BB-86A1-E5A80CC410E5Q37329074-BC55DBCE-2CB8-4AC2-B5AC-3E7BDEAEED53Q37488232-3B76C2D7-DBDC-400D-988F-350F62CFE1A6Q38521383-9E152591-9DFF-4685-AD84-4307EBCBB896Q38769811-E88F5437-4592-454F-B557-71BDBE1AB4EFQ38807006-F005D04F-275F-492F-86F6-B46C21346AC9Q38933554-D5F53441-F962-4ECD-8119-6C4956A574F6Q38968548-6A288137-CB05-4261-AE59-0135606CC099Q38991358-B5B8E3BD-4542-4235-A624-87DF380BB1FFQ39158058-A6361742-6B3A-4202-BE40-2A65DD5AADE7Q39210558-E5047EB5-9390-4C16-BC85-DCC2ECC7513EQ39318754-1BA2C695-3F3C-4682-A04E-4F0D3ECCAAFEQ39832762-9451A584-35B9-4266-ADA3-D5E203A7B0B7Q40533256-C73B1215-6432-4603-BEFC-F8E062ED5183Q40695075-BE71CDEE-58E7-401B-8799-06416D8995AAQ40815228-AD362649-A083-4FB4-9AD2-EE630B3549B8Q46142019-291EBA2E-4BC8-45D8-B4E0-22345BC7A9B5Q47704613-07274123-2CA6-4263-8251-D108D7DD9C3BQ47813610-F3717EDE-8542-469F-9522-2DA1A215B9E0Q48225577-4F37791B-8992-4FE7-A093-F4A1E05F808CQ48230065-9FC4F445-A0BE-47E8-9A2A-D716E0CC9BEFQ48324692-1804CCFA-36ED-4930-BF1C-7710031C1403Q48362769-02B44708-2515-47C2-B671-8DBB098DCBB6Q51286859-E9A5559A-6FEA-440F-A3B0-DA2C29D235B7Q55001725-9D30D538-EE10-4BA9-986F-70A8337C8FE2Q57226615-C2FF2DB7-4F26-4368-A156-BB6A12E9118DQ58585474-C73411F6-D650-4684-BDF9-FEDBE335A256
P2860
An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
@en
type
label
An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
@en
prefLabel
An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
@en
P2093
P1476
An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
@en
P2093
Claude Libert
Lien Dejager
Lynda Grine
P356
10.1016/J.CYTOGFR.2014.10.009
P577
2014-10-31T00:00:00Z